上半年亏损超4000万元，深圳这家医疗企业递表港交所

Core Insights - Shenzhen Micotian Biomedical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its capital market journey [1] - The company specializes in biomedical technology research and commercialization, aiming to enhance its market reach and R&D capabilities through this listing [1] Company Overview - Micotian is a global provider of medical solutions, offering a comprehensive product portfolio that meets clinical needs across various healthcare settings [2] - As of June 30, 2025, the company has commercialized over 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products, with a presence in over 140 countries and regions [2] - In China, Micotian's products cover more than 6,000 hospitals, including approximately 90% of top-tier hospitals [2] Product Leadership - In the life support sector, Micotian has developed innovative products, including the world's first remote infusion control system and China's first self-developed multi-channel infusion workstation [2] - The company ranks first in sales in the Chinese infusion workstation market from 2018 to 2024 and also leads in the enteral nutrition pump market from 2021 to 2024 [2] Financial Performance - Despite leading market positions in certain medical segments, Micotian has reported losses in recent years, with revenues of approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million for the six months ending June 30 in 2022, 2023, 2024, and 2025, respectively [4] - The company reported losses of approximately RMB 226.16 million, RMB 64.51 million, RMB 96.62 million, and RMB 40.97 million for the same periods [4] Revenue Trends - Revenue from life support products fluctuated, increasing from RMB 415.8 million in 2022 to RMB 564.1 million in 2023, then decreasing to RMB 494.1 million in 2024 due to short-term market adjustments [5] - In the first half of 2025, life support product sales increased by 20.8% year-on-year, driven by strategic global expansion [5] Minimally Invasive Products - Sales revenue from minimally invasive products grew from RMB 38.6 million in 2022 to RMB 58.65 million in 2023, and further to RMB 72.13 million in 2024, with a 16.8% increase in the first half of 2025 [6] - The growth is attributed to an expanded customer base and increased product sales in both domestic and international markets [6] In Vitro Diagnostics - Revenue from in vitro diagnostic products rose from RMB 11.55 million in 2022 to RMB 16.26 million in 2023, and then to RMB 18.4 million in 2024, driven by an expanding product portfolio and market coverage [7]